New remedies are required for the treatment of diabetic neuropathic pain (DNP) due to insufficient efficacy of available therapies. Here, we used chemogenetic approaches combined with in vivo pharmacology to elucidate the role of basolateral amygdala (BLA) astrocytes in DNP pathogenesis and provide new insights into therapeutic strategies for DNP.
- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Advocacy
- Careers
- About
- For Pain Patients and Professionals